Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus zoledronic acid for prevention of skeletal-related events in advanced cancer or multiple myeloma with bone involvement
2006-000848-65Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bone metastases and multiple myeloma (MM) comparing Denosumab with Zoledronic acid (2 arms). Primary endpoint: Time to first on-study skeletal-related event. Started Jun 2006; status: completed.
02
Drugs
denosumabzoledronic acid
03
Conditions
bone metastasesmultiple myeloma (MM)
Beyond the preview
Go deeper on 2006-000848-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000848-65.